NASDAQ: KRON
Kronos Bio Inc Stock

$0.89-0.01 (-1.11%)
Updated Apr 30, 2025
Why Price Moved
KRON Price
$0.89
Fair Value Price
$1.65
Market Cap
$54.45M
52 Week Low
$0.69
52 Week High
$1.60
P/E
-0.62x
P/B
0.62x
P/S
5.8x
PEG
N/A
Dividend Yield
N/A
Revenue
$9.85M
Earnings
-$86.08M
Gross Margin
100%
Operating Margin
-874.08%
Profit Margin
-874.1%
Debt to Equity
0.42
Operating Cash Flow
-$65M
Beta
1.27
Next Earnings
May 7, 2025
Ex-Dividend
N/A
Next Dividend
N/A

KRON Overview

Kronos Bio Incorporated is a biopharma developing novel cancer therapeutics. Its product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks that drive oncogenic activity. The company's lead product candidate is entospletinib (ENTO), an orally administered, selective spleen tyrosine kinase inhibitor for acute myeloid leukemia patients. It is also developing KB-0742, a bioavailable inhibitor of cyclin dependent kinase 9 for the treatment of MYC-amplified solid tumors. Kronos Bio was incorporated in 2017 and is headquartered in San Mateo, CA.

Zen Rating

Our proven quant model uses 115 proprietary factors, including AI, to determine KRON's potential to beat the market

Zen Rating Component Grades

N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.

Industry: Biotech

Industry Rating
F
KRON
Ranked
Unranked of 462

Top Ranked Stocks in Industry

View Top Biotech Stocks

Be the first to know about important KRON news, forecast changes, insider trades & much more!

KRON News

Overview

Due Diligence Score

Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how KRON scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

KRON ($0.89) is undervalued by 45.91% relative to our estimate of its Fair Value price of $1.65 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
KRON ($0.89) is significantly undervalued by 45.91% relative to our estimate of its Fair Value price of $1.65 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
KRON is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more KRON due diligence checks available for Premium users.

Valuation

KRON fair value

Fair Value of KRON stock based on Discounted Cash Flow (DCF)

Price
$0.89
Fair Value
$1.65
Undervalued by
46.09%
KRON ($0.89) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
KRON ($0.89) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
KRON is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

KRON price to earnings (PE)

For valuing profitable companies with steady earnings

Company
-0.62x
Industry
-162.28x
Market
29.18x

KRON price to book (PB)

For valuing companies that are loss-making or have lots of physical asset

Company
0.62x
Industry
4.45x
KRON is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

KRON's financial health

Profit margin

Revenue
$2.3M
Net Income
-$25.8M
Profit Margin
-1,137.1%
KRON's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
KRON's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$124.4M
Liabilities
$36.8M
Debt to equity
0.42
KRON's short-term assets ($115.23M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
KRON's short-term assets ($115.23M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
KRON's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
KRON's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$12.8M
Investing
$22.4M
Financing
$82.0k
KRON's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

KRON vs Biotech Stocks

TickerZen RatingMarket Cap1d %P/EP/B
KRON$54.45M-0.67%-0.62x0.62x
ACETD$54.74M+6.43%-0.50x0.29x
MRSN$53.97M+17.34%-0.77x-5.68x
OKYO$53.79M0.00%-4.17x-7.44x
CYCC$53.49M-15.13%-0.12x-24.61x

Kronos Bio Stock FAQ

What is Kronos Bio's quote symbol?

(NASDAQ: KRON) Kronos Bio trades on the NASDAQ under the ticker symbol KRON. Kronos Bio stock quotes can also be displayed as NASDAQ: KRON.

If you're new to stock investing, here's how to buy Kronos Bio stock.

What is the 52 week high and low for Kronos Bio (NASDAQ: KRON)?

(NASDAQ: KRON) Kronos Bio's 52-week high was $1.60, and its 52-week low was $0.69. It is currently -44.19% from its 52-week high and 29.42% from its 52-week low.

How much is Kronos Bio stock worth today?

(NASDAQ: KRON) Kronos Bio currently has 60,969,214 outstanding shares. With Kronos Bio stock trading at $0.89 per share, the total value of Kronos Bio stock (market capitalization) is $54.45M.

Kronos Bio stock was originally listed at a price of $27.07 in Oct 9, 2020. If you had invested in Kronos Bio stock at $27.07, your return over the last 4 years would have been -96.7%, for an annualized return of -57.38% (not including any dividends or dividend reinvestments).

How much is Kronos Bio's stock price per share?

(NASDAQ: KRON) Kronos Bio stock price per share is $0.89 today (as of Apr 30, 2025).

What is Kronos Bio's Market Cap?

(NASDAQ: KRON) Kronos Bio's market cap is $54.45M, as of May 1, 2025.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Kronos Bio's market cap is calculated by multiplying KRON's current stock price of $0.89 by KRON's total outstanding shares of 60,969,214.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.